We would love to hear your thoughts about our site and services, please take our survey here.
King, is there any record of a payment or future payments from those contracts
Pauldark & topup, wondered if either of you still held #OBC ?
I know it’s dropped back a lot since the dizzy basically pumped heights of £1.40s-£1.50s but goes to show how tech stocks can be .
I remember it hanging around 60 - 80p for quite awhile before that happened.
Hopefully if this gets through it will be well received.
Hi,
The http://www.sense-esco.eu/en/ projects in Croatia, 2 of..Belisce I & 2 I believe.
Also Polygen.
Today is good news but why no news on older contracts.
These projects I think are still mentioned on eqtecs website.
Shame the update doesn’t include any information on Croatia as they where announced years ago but nothing since.
Congratulations Calculatedumb on posting more rubbish, you’re outstanding contribution still continue
This month Sceneplay / Entertainment Ai renewed its patent which was probably part of the hold up.
Now we have a set date to look towards and expect an RNS EGM outlining how this will come to market.
As Topup says let’s hope this one crosses the line and RS has kept the dilution down.
Look forward to more information to be honest as this stock has been really stealth and hard to find things.
Fingers crossed still and Gla
They said they would pass it along to RS. Like I said, I didn't expect a reply.
How quick do you think these things happen Aim, you have to take into account how complicated they are with finance , shares, possible acquisitions/mergers and the tech it self.
This may be being headed by Ann but that's just one person of many involved.
I'm absolutely broke and hope this can be done but no amount of moaning on here is going to change that.
Aim, I got a reply from Walbrook within a couple of hours but then maybe I have a better rapport with them than you.
I asked them to send an email along to RS about updates but never expect a reply from RS.
They will update us when they have something concrete to update us with and not before as expected.
All the money and shares are safe in a holdings company which updated its paper work via companies house very recently so you shouldn't worry about that.
I noticed that Entertainment AI has recently updated its Principal activity description with its latest Confirmation Statement.
It reads ;
Ready-made interactive leisure and entertainment software development Information technology consultancy activities.
Contact broker to vote on resolutions before Luke winds the company up for being the most useless CEO in history.
In Geneva Switzerland for AI For Good Global Summit.
Drumming up support one last time ?
First register of company was back in 2007
Was granted for scene play aka entertainment ai in July 2009
Trials
Edit
Drug development and pre-clinical trials focus on non-human subjects and work on animals such as rats. This is the most inexpensive phase of testing.[citation needed]
The Food and Drug Administration mandates a 3 phase clinical trial testing that tests for side effects and the effectiveness of the drug with a single phase clinical trial costing upwards of $100 million.[9]
After a drug has passed through all three phases, the pharmaceutical company can move forward with a New Drug Application from the FDA. In 2014, the FDA charged between $1 million to $2 million for an NDA.[10]
Failed drugs
Edit
The processes of "discovery" and clinical trials amounts to approximately 12 years from research lab to the patient, in which about 10% of all drugs that start pre-clinical trials ever make it to actual human testing.Citation needed Each pharmaceutical company (who have hundreds of drugs moving in and out of these phases) will never recuperate the costs of "failed drugs". Thus, profits made from one drug need to cover the costs of previous "failed drugs".
Relationship
Edit
Overall, research and development expenses relating to a pharmaceutical drug amount to the billions. For example, it was reported that AstraZeneca spent upwards on average of $11 billion per drug for research and developmental purposes.[9] The average of $11 billion only comprises the "discovery" costs, pre-clinical and clinical trial costs, and other expenses.[citation needed] With the addition of "failed drug" costs, the $11 billion easily amounts to over $20 billion in expenses.[citation needed] Therefore, an appropriate figure like $60 billion would be approximate sales figure that a pharmaceutical company like AstraZeneca would aim to generate to cover these costs and make a profit at the same time.[citation needed]
Total research and development costs provide pharmaceutical companies a ballpark estimation of total expenses. This is important in setting projected profit goals for a particular drug and thus, is one of the most necessary steps pharmaceutical companies take in pricing a particular drug.[citation needed]
Research on costs
Edit
Tufts Center for the Study of Drug Development has published numerous studies estimating the cost of developing new pharmaceutical drugs. In 2001, researchers from the Center estimated that the cost of doing so was $802 million,[11] and in 2014, they released a study estimating that this amount had risen to nearly $2.6 billion.[12] The 2014 study was criticized by Medecins Sans Frontieres, which said it was unreliable because the industry's research and development spending is not made public.[13] Aaron Carroll of the New York Times also criticized the study, saying it "contains a lot of assumptions that tend to favor the pharmaceutical industry."[14] The Center's 2016 estimate, published in the Journal of Health Economics, found the cost to have averaged $2.87 billion (in 2013 dollars).[15]
Totally agree with IW.
I personally expect route 2 as done by many small pharmaceutical companies today as a secondary backup for the FDA.
Gla
Heard something similar, the wait continues.
An old presentation from DEC 17 but very much worth a watch.
Company is 10 years old building .
Ann Greenberg has worked with a lot of major companies.
Apple, Sony, Napster, Warner Bros etc.
Very impressive Woman.
https://youtu.be/nmcYeYXLJjQ
Anngreenberg.com
@Entertainai
@sceneplay
@AnnGreenberg
@DeanoG78
Ann Greenberg is a serial entrepreneur and inventor. Ann’s new venture, Entertainment AI™ (Sceneplay, Inc.) is developing groundbreaking, patented systems using AI and Blockchain to automate media creation, distribution and analysis. In 1998, Ann co-founded Gracenote, the world’s largest entertainment data company, and the first crowdsourced company. Gracenote helps consumers to discover and engage with relevant, personalized content across platforms—from smart TVs, to smartphones and the streaming media in their cars. Gracenote was acquired by Nielsen for $560M in 2017. Prior to founding Gracenote, Ann co-founded ION, an early digital studio who worked with David Bowie, Brian Eno, Todd Rungren, The Residents, Primus and leading technology companies. Ann also ran marketing for Edward R Pressman Film Corporation.
Collapse
1 June 2018
Transaction Update
Further to the announcement of 22 March 2018, Draganfly Investments Limited is pleased to announce that it has entered into binding heads of terms with a private entity owning copper exploration and development assets in Zambia, to undertake a reverse takeover in conjunction with a placing of new shares in the enlarged group.
Due diligence is underway and the Company hopes to announce exchange of contracts and the fundraising, which are subject, inter alia, to successful completion of due diligence, shareholder approval and admission to AIM, during Q2/Q3 2018, at which point the Company will apply for the suspension of trading of the Company's shares on AIM to be lifted.
Luke, Your Killing Me Softly here.